Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)
The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia
Sponsor: Aarhus University Hospital
Listed as NCT02192450, this PHASE4 trial focuses on Nocturnal Hypoglycemia and Recurrent Severe Hypoglycaemia and remains completed. Sponsored by Aarhus University Hospital, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE4
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE4
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aarhus University Hospital
- Copenhagen University Hospital, Denmark
- Esbjerg Hospital - University Hospital of Southern Denmark
- Hvidovre University Hospital
- Nordsjaellands Hospital
- Odense University Hospital
- Steno Diabetes Center Copenhagen
- Zealand University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .